【摘要】 目的探讨非小细胞肺癌(NSCLC)患者血清微小RNA-155(microRNA-155,miR-155)水平及其临床意义。方法采用荧光实时定量逆转录聚合酶链反应法检测58例NSCLC患者和42例健康体检者血清miR-155的表达,并分析其与临床、病理资料的相关性。结果 NSCLC患者血清miR-155的表达水平明显升高,而且其表达与组织分化、临床分期、淋巴结转移显著相关(P<0.05),而在不同年龄、性别和病理类型患者间差异无统计学意义(P>0.05)。结论 NSCLC患者血清miR-155水平与肿瘤分型、临床分期和术后复发显著相关,可以作为NSCLC诊断和预后判断的肿瘤标志物。更多还原

【Abstract】 Objective To explore the expression of miR-155 in non-small cell lung cancer(NSCLC)and its clinical value. Methods The levels of miR-155 in serums was detected by real-time quantitative reverse transcription polymerase chain reaction(qRT-PCR) in 58 patients with NSCLC and 42 normal persons. Results The expression of miR-155 in NSCLC was increased, furthermore, it was related to histo-differentiation, clinical stage and lymph node metastasis (P<0.05).No correlation was found in patients with different age,sex and pathological type (P>0.05). Conclusions miR-155 might play an important role in NSCLC. It could be a prognostic marker for NSCLC.更多还原